Facebook
Twitter
LinkedIn
ForwardState of the Science Symposia Series: Metabolic Pathways and Therapeutics to Promote Resilience, Rehabilitation
Target Audience
The content of the sessions will benefit civilians, veterans, and military service members, their families, care-givers, community-based organizations, government agency personnel, students, residents, and healthcare providers.
Learning Objectives
The overall objective of this course is to provide participants with an overview of current techniques utilized and programs implemented in the area of research and treatment related to metabolic pathways. The course will attain this objective by showcasing research talks regarding the metabolic pathways and therapeutics to increase resilience, rehabilitation and the ageing process.
Additional Information
| Attachment | Size |
|---|---|
 SOS Agenda- Oct 25 2019 (DJF- PFP-2) (003) APPROVED.pdf | 640.68 KB |
0800 – 0830 | Check-In │ Continental Breakfast |
0830 – 0840
0840 - 0900 | Opening Remarks - Welcome COL (ret) Paul Pasquina, MD Department Chief and Chair, PM&R Walter Reed National Military Medical Center/Uniformed Services University of the Health Sciences (USUHS)
The Importance of Nutrition and Metabolic Research to Military Readiness and Resilience Patricia Deuster, PhD, MPH, FACSM Professor and Director Consortium for Health and Military Performance Uniformed Services University of the Health Sciences (USUHS)
|
0900 – 0925 | Overview of Calorie Restriction and Aging as a Field of Research Yih-Woei Fridell, PhD Program Officer Division of Aging Biology National Institute on Aging, NIH
|
0925 – 0950
| Time-Restricted Feeding Rafael de Cabo, PhD National Institute on Aging
|
0950 – 1015
1015 – 1040
1040 - 1100
1100 – 1125
1125 - 1150
| Low Calorie Diet for Chemotherapy Augmentation Sebastian Brandhorst, PhD University of Southern California
Metformin Jamie Nicole Justice, PhD Wake Forest School of Medicine
BREAK
Glycolytic Inhibition Donald Ingram, PhD Pennington Biomedical Research Center
Acarbose Daniel Larry Smith, PhD University of Alabama at Birmingham |
1150 – 1215
1215 - 1300 | Sirtuin Activators and NAD Precursors Joseph Baur, PhD University of Pennsylvania
LUNCH
|
1325 – 1350 | Rapamycin Arlan Richardson, PhD University of Oklahoma Health Science Center
|
1350 – 1415
1415 – 1430 | Ketone Bodies John Newman, MD, PhD University of California San Francisco (UCSF)
BREAK
|
1430 – 1455 | Senolytic Yi Zhu, PhD Mayo Clinic Rochester
|
1455 – 1520
1520 – 1545
1545-1600 | PARP Activators Sajish Mathew PhD University of South Carolina College of Pharmacy
Mitochondrial Derived Peptides Su-Jeong Kim University of Southern California
Closing Remarks/Adjournment William K. Smith, MD COL(ret), Paul Pasquina, MD Conference Co-Chair, Assistant Professor Professor and Chair, Department of PM&R Department of PM&R, USUHS WRNMMC & USUHS |
Faculty Disclosure
All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by patients.
The following relevant financial relationships were disclosed:
- Sebastian Brandhorst is a Scientific Director for the Create Cures Foundation.
- Donald K. Ingram is a consultant for Isagenix International, Gilbert, AZ and Suntory Wellness, Osaka, Japan and is a stockholder for GeroScience, Inc, Baltimore, MD and Prolongevity Technologies, Baton Rouge, LA.
- Joseph Baur received grant and research support form Metro Biotech, Elysium Health, Calico (Applied) he also serves as a consultant for Mitobridge, and Calico.
- Shin-ichiro Imai receives patent and licensing fees from MetroBiotech, USA, and Teijin Limited, Japan, through the Washington University.
- John Newman is a stockholder for BMB Therapeutics, Ltd.
- Yi Zhu is a stockholder and receives patents fee on senolytic drugs, held by Mayo Clinic, and licensed to Unity Biotechnology. He has received stocks from Unity Biotechnology.
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The University of Pittsburgh School of Medicine designates this live activity for a maximum of 6.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Other health care professionals
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 6.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 6.00 Attendance